PharmaBlock, a global CDMO focused on innovative chemistry and low-carbon manufacturing, opened a new R&D facility in West Chester, PA. The facility expands the company’s footprint in the U.S. and enables more efficient process R&D services and fast delivery of clinical-stage GMP projects to global partners.

The new West Chester site covers an area of four acres, with 30,000 square feet of usable lab space. The site has a well-established R&D infrastructure, including process R&D labs, GMP suites, clean rooms, and GMP analytical labs. The new site also enables flow chemistry, micro-packed bed hydrogenation, and solid-state chemistry capabilities.

“We are excited to celebrate the grand opening of our new research facility, which represents a significant milestone for our company,” said Jing Li, president of PharmaBlock (USA), Inc. “This state-of-the-art facility will enable us to provide our clients with the highest quality research and development solutions, and we look forward to continuing to innovate and advance.”

PharmaBlock took its first step in the U.S. in 2012, with the sales and customer service office in the Bay Area of California. In 2017, the company established the process R&D facility in Hatfield, PA. With 15,000 square feet of lab space, the Hatfield site is fully equipped with process R&D labs and GMP kilo-labs. Multiple API and GMP projects have been delivered to U.S.-based clients from this site. The West Chester site is a key addition to enhance the delivery of clinical-stage API projects at PharmaBlock USA.

Furthermore, a GMP manufacturing facility for intermediates and APIs with reactors of 500 L to 2,000 L is also planned at the West Chester site, expected to operate in 2024.

According to the company, expanding the global footprint is one of the initiatives that PharmaBlock has been working on to strengthen supply chain resilience. In addition to the U.S. facilities, PharmaBlock has multiple R&D and GMP manufacturing facilities set up in China to provide CMC solutions for intermediates, RSMs, APIs, and drug products from development to commercialization. PharmaBlock is also seeking opportunities to expand its capabilities and capacity in other parts of the world.